These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30726458)

  • 1. Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients.
    Wambier CG; Hoekstra TA; Wambier SPF; Bueno Filho R; Vilar FC; Paschoal RS; Roselino AM; Frade MAC; Foss NT
    An Bras Dermatol; 2019; 94(1):17-23. PubMed ID: 30726458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment and Comparison of Performance of ABCD-10 and SCORTEN in Prognostication of Epidermal Necrolysis.
    Koh HK; Fook-Chong S; Lee HY
    JAMA Dermatol; 2020 Dec; 156(12):1294-1299. PubMed ID: 33084873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis: The Role of Novel Inflammatory Markers and Proposed Revision of SCORTEN (Re-SCORTEN).
    Koh HK; Fook-Chong SMC; Lee HY
    JAMA Dermatol; 2022 Feb; 158(2):160-166. PubMed ID: 34935871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the Accuracy of ABCD-10 and SCORTEN in Predicting the In-Hospital Mortality of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multi-Institutional Study from Central China.
    Suo H; Jiang B; Sun X; Dong J; Alamgir M; Guan X; Su H; Liu Y; Xia Y; Zhou N; Feng A; Tao J
    Dermatology; 2022; 238(4):736-744. PubMed ID: 34875648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and costs of patients with toxic epidermal necrolysis: a 27-year retrospective study.
    Oen IM; van der Vlies CH; Roeleveld YW; Dokter J; Hop MJ; van Baar ME
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2444-50. PubMed ID: 26416341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.
    Noe MH; Rosenbach M; Hubbard RA; Mostaghimi A; Cardones AR; Chen JK; Cotliar J; Davis MDP; Dominguez A; Fox LP; Hughey LC; Kaffenberger BH; Kroshinsky D; Kwong BY; Miller DD; Musiek A; Ortega-Loayza AG; Sharon VR; Shinkai K; Summers EM; Wanat KA; Wetter DA; Worswick S; Margolis DJ; Gelfand JM; Micheletti RG
    JAMA Dermatol; 2019 Apr; 155(4):448-454. PubMed ID: 30840032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).
    Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A
    Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of Toxic Epidermal Necrolysis.
    Bansal S; Garg VK; Sardana K; Sarkar R
    Int J Dermatol; 2015 Jan; 54(1):e18-26. PubMed ID: 25534407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
    Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
    Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Duplisea MJ; Roberson ML; Chrisco L; Strassle PD; Williams FN; Ziemer CM
    J Am Acad Dermatol; 2021 Oct; 85(4):873-877. PubMed ID: 33940101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Antoon JW; Goldman JL; Lee B; Schwartz A
    Pediatr Dermatol; 2018 Mar; 35(2):182-187. PubMed ID: 29315761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis.
    Guégan S; Bastuji-Garin S; Poszepczynska-Guigné E; Roujeau JC; Revuz J
    J Invest Dermatol; 2006 Feb; 126(2):272-6. PubMed ID: 16374461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of histologic features of toxic epidermal necrolysis.
    Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
    J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study.
    Sekula P; Liss Y; Davidovici B; Dunant A; Roujeau JC; Kardaun S; Naldi L; Schumacher M; Mockenhaupt M
    J Burn Care Res; 2011; 32(2):237-45. PubMed ID: 21228709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China.
    Zhu QY; Ma L; Luo XQ; Huang HY
    J Burn Care Res; 2012; 33(6):e295-308. PubMed ID: 22955159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis.
    Sorrell J; Anthony L; Rademaker A; Belknap SM; Callahan S; West DP; Paller AS
    Pediatr Dermatol; 2017 Jul; 34(4):433-437. PubMed ID: 28508417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RDW-SD and PCT Are Potential Prognostic Factors for In-hospital Death in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
    Zhang L; Lan Y; Qi B; Shuai P; Hou Q; Liu W; Wang Q
    Allergy Asthma Immunol Res; 2023 Nov; 15(6):812-824. PubMed ID: 37957797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience.
    Nizamoglu M; Ward JA; Frew Q; Gerrish H; Martin N; Shaw A; Barnes D; Shelly O; Philp B; El-Muttardi N; Dziewulski P
    Burns; 2018 May; 44(3):603-611. PubMed ID: 29029855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinico- Therapeutic Study of Stevens Johnson Syndrome-Toxic Epidermal Necrolysis and Prognostic Significance of SCORTEN in Indian Patients.
    Jangid NC; Choudhary AN; Shah BJ; Shah SR; Vyas HR; Mistry D
    Indian J Dermatol; 2024; 69(1):24-31. PubMed ID: 38572027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.